Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 30fludarabine phosphate 19Specimen Handling 15Cyclophosphamide 15Biopsy 14Peripheral Blood Stem Cell Transplantation 13Busulfan 13Imatinib Mesylate 12Etoposide 12Filgrastim 11Decitabine 11Azacitidine 11Methotrexate 10Idarubicin 10Daunorubicin 10Cyclosporine 9X-Rays 8Tacrolimus 8Antilymphocyte Serum 8tipifarnib 7Vorinostat 7Stem Cell Transplantation 7Radiotherapy 7Magnetic Resonance Spectroscopy 7fludarabine 6decitabine and cedazuridine drug combination 6Phantoms, Imaging 6Topotecan 5Prednisone 5Nuclear Medicine Department, Hospital 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × luspatercept × Myeloid × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡